Vilar Helena, Nobre E Lacerda, Jorge Z, Lopes C, André S, Salgado L, Macedo A, De Castro J Jácome
Serviço de Endocrinologia, Hospital Militar Principal, Lisboa, Portugal.
Acta Med Port. 2006 Jul-Aug;19(4):295-300. Epub 2007 Jan 23.
Thyroid diseases are an area of particular interest to this Department, constituting 30% of the 3561 patients observed over the last 5 years (when group consultations were set up and outpatient data computerised).
To determine the prevalence and aetiologies of Hyperthyroidism (HT) in outpatient clinic and characterise diagnostic and therapy practice.
All files of patients diagnosed with HT treated in the department over the last 5 years were reviewed. Of a total of 105 files, 96 were analysed. The data analysed included: demographic data, aetiology of disease, complementary diagnostic test reported, treatment options and follow-up. The data was analysed independently depending on whether 1st consultation occurred before or after 1999. The variables were analysed using descriptive statistical methods, namely frequency and contingency tables for categoric variables and mean, standard deviation, maximum and minimum values for continuous variables.
Of the patients evaluated, 72% were female and 28% male, with an average age of 50. 49.0% had Graves' Disease (GD); 14.6% toxic multinodular goitre (TMNG); 11.5% autoimmune HT; 10.4% iatrogenic HT; 7.3% subacute thyroiditis and 7.3% toxic adenoma (TA). Medical treatment was 1st option for 92% of patients with GD (40.4% of cases combined with levothyroxine); 5% received 131Iodine treatment and 3% underwent surgery. In this group, 6 months after suspension of medical treatment, 30.4% had suffered a relapse. Of the patients who suffered a relapse, 42% underwent surgery and 28% received 131Iodine treatment. The remaining 30% made a second attempt with synthetic antithyroid drugs. For patients with TMNG, surgery was the 1st treatment option for the majority of patients (78.5%), followed by 131Iodine (14.2%). 70% of patients with toxic adenoma underwent surgery and 30% 131Iodine treatment. For other pathologies, namely autoimmune HT, iatrogenic HT and subacute thyroiditis, the option was medical treatment.
Hyperthyroidism was diagnosed in 3.5% of patients observed as outpatients in this Department. GD was the most prevalent form of HT (49%). Medical treatment is the first treatment option (92%) for GD. 6 months after suspension of medical treatment, 30% of patients had suffered a relapse of GD. For these patients, surgery was the 1st option. For both TMNG and TA, surgery was the first treatment option.
The adverse effects that occurred with ATDs (antithyroid drugs) were detected in 4,1% patients; one case of agranulocytosis with propylthiouracil, 2 cases of allergic reactions--rash (one due to the use of methimazole and the other to propylthiouracil), and one case of minor hepatocellular toxicity. In all patients there was improvement after stopping medical treatment.
甲状腺疾病是本部门特别关注的领域,在过去5年(设立集体会诊并将门诊数据计算机化时)观察的3561例患者中占30%。
确定门诊甲亢(HT)的患病率和病因,并描述诊断和治疗方法。
回顾了过去5年在本部门接受治疗的所有确诊为HT的患者档案。在总共105份档案中,分析了96份。分析的数据包括:人口统计学数据、疾病病因、报告的辅助诊断检查、治疗选择和随访情况。根据首次会诊发生在1999年之前还是之后,对数据进行独立分析。使用描述性统计方法分析变量,即分类变量的频率和列联表,以及连续变量的均值、标准差、最大值和最小值。
在评估的患者中,72%为女性,28%为男性,平均年龄为50岁。49.0%患有格雷夫斯病(GD);14.6%为毒性多结节性甲状腺肿(TMNG);11.5%为自身免疫性HT;10.4%为医源性HT;7.3%为亚急性甲状腺炎,7.3%为毒性腺瘤(TA)。92%的GD患者首选药物治疗(40.4%的病例联合左甲状腺素);5%接受131碘治疗,3%接受手术治疗。在这组患者中,停药6个月后,30.4%复发。在复发的患者中,42%接受了手术,28%接受了131碘治疗。其余30%再次尝试使用合成抗甲状腺药物。对于TMNG患者,大多数患者(78.5%)首选手术治疗,其次是131碘(14.2%)。70%的毒性腺瘤患者接受了手术,30%接受了131碘治疗。对于其他病理类型,即自身免疫性HT、医源性HT和亚急性甲状腺炎,选择药物治疗。
本部门门诊观察的患者中有3.5%被诊断为甲亢。GD是HT最常见的形式(49%)。药物治疗是GD的首选治疗方法(92%)。停药6个月后,30%的患者GD复发。对于这些患者,手术是首选。对于TMNG和TA,手术都是首选治疗方法。
4.1%的患者检测到抗甲状腺药物(ATD)的不良反应;1例因丙硫氧嘧啶导致粒细胞缺乏症,2例过敏反应——皮疹(1例因使用甲巯咪唑,另1例因丙硫氧嘧啶),1例轻度肝细胞毒性。所有患者停药后均有改善。